<DOC>
	<DOCNO>NCT00158782</DOCNO>
	<brief_summary>This Phase I , dose find study evaluate safety tolerability lapatinib , dual tyrosine kinase inhibitor , GW786034 , anti-angiogenesis agent , give together . The study first find best dos use safety blood concentration data agent . This do enrolling stepwise , cohorts 3 patient last patient enrol must reach least Day 22 continuous daily dose next cohort increase dose begin . If patient cohort dose limit toxicity Day 22 , 3 patient study dose . If 2 6 patient dose limit toxicity within first 22 day , next cohort receive next lowest dose . Otherwise cohort increase dose one two agent . The second stage study administer best dos agent 16 patient study safety collect blood concentration data ( blood sample second phase compare first phase ) . The second stage advantage use best dose ( decrease chance receive sub-therapeutic dose ) collect blood sample require slightly long clinic visit .</brief_summary>
	<brief_title>Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis advance solid tumor refractory standard therapy standard therapy . Females eligible : ) Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : hysterectomy . bilateral oophorectomy ( ovariectomy ) . bilateral tubal ligation . postmenopausal ( demonstration total cessation menses 1 year ) . childbearing potential , negative serum pregnancy test screening , agree one following : IUD document failure rate le 1 % per year . vasectomized partner sterile prior female patient 's entry sole sexual partner female . complete abstinence sexual intercourse 14 day exposure investigational product , throughout clinical trial , least 14 day last dose investigational product . doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . ECOG ( Eastern Cooperative Oncology Group ) PS 0 1 . Adequate bone marrow function . Platelets great equal 75,000/mm3 . ANC great equal 1,500/mm3 ( 1.5 x 109/L ) . Hgb great equal 9 g/dL ( 5 mmol/L ) . CLcr &gt; 50 mL/min calculate CockcroftGault formula . Total bilirubin less equal 1.5 x upper limit normal . PT/INR/PTT le equal 1.2 x upper limit normal . AST/ALT le equal 3 x upper limit normal . Has LVEF within normal range 50 % base MUGA/ECHO . Urinalysis protein &lt; 2 ( negative , trace , 1 ) . NOTE : If urinalysis 2 great 24 hour urine protein must demonstrate less 1 gram protein 24 hour patient eligible enrollment . Able swallow retain oral medication . Has life expectancy least 12 week . Exclusion criterion : Had prior treatment either study drug . Has brain metastasis . Uncontrolled hypertension ( BP high 150/90 SBP/DBP ) . Have heart failure . Have DVT ( deep vein thrombosis ) arterial thrombosis , MI ( myocardial infarction ) , angina , angioplasty and/or stenting within last 3 month . Has allergy drug similar lapatinib ( e.g . allergic Iressa ( gefitinib ) Tarceva ( erlotinib ) . Is use therapeutic dos anticoagulant . Has major surgery , hormonal therapy , chemotherapy , radiotherapy , investigational agent within last 28 day . Pregnant lactating . History current GI ( gastrointestinal ) condition alters stomach gut empty normal ( e.g . major surgery stomach ) . Bowel obstruction chronic diarrhea . Psychological geographical condition would prevent him/her good candidate . Do accessible vein venipuncture . History prolong QTc ECG .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cancer GW786034 Lapatinib Pazopanib</keyword>
</DOC>